Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Cytometric analysis of cell suspension generated by cavitron ultrasonic surgical aspirator in pediatric brain tumors

M. Vaskova, M. Tichy, J. Zamecnik, P. Liby, D. Kuzilkova, A. Vicha, J. Hrabeta, T. Kalina, J. Stary, O. Hrusak,

. 2019 ; 143 (1) : 15-25. [pub] 20190302

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19034739

Grant support
15-26588A Ministerstvo Zdravotnictví Ceské Republiky
UNCE 204012 Univerzita Karlova v Praze
LO1604 Ministerstvo Školství, Mládeže a Tělovýchovy
NV15-26588A MZ0 CEP Register

PURPOSE: The aim of this study was to test the possibility of using specimens obtained by a cavitron ultrasonic surgical aspirator (CUSA) in flow and mass cytometry investigations of pediatric brain tumors. METHODS: CUSA specimens obtained from 19 pediatric patients with brain tumors were investigated. Flow and mass cytometry methods were applied to analyze the composition of material collected using the CUSA. Cell suspensions were prepared from CUSA aspirates. Then sample viability was assessed by conventional flow cytometry and subsequently stained with a panel of 31 metal-labeled antibodies. RESULTS: Viability assessment was performed using conventional flow cytometry. Viability of cells in the acquired samples was below 50% in 16 of 19 cases. A mass cytometry investigation and subsequent analysis enabled us to discriminate brain tumor cells from contaminating leukocytes, whose proportions varied across the specimens. The addition of the viability marker cisplatin directly into the mass cytometry panel gave the means to selecting viable cells only for subsequent analyses. The proportion of non-viable cells was higher among tumor cells compared leukocytes. CONCLUSIONS: When the analysis of the tumor cell immunophenotype is performed with markers for determining viability, the expression of the investigated markers can be evaluated. Suitable markers can be selected by high-throughput methods, such as mass cytometry, and those that are diagnostically relevant can be investigated using flow cytometry, which is more flexible in terms of time.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19034739
003      
CZ-PrNML
005      
20201015161711.0
007      
ta
008      
191007s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11060-019-03135-w $2 doi
035    __
$a (PubMed)30827009
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vaskova, Martina $u CLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic. martina.vaskova@lfmotol.cuni.cz. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic. martina.vaskova@lfmotol.cuni.cz.
245    10
$a Cytometric analysis of cell suspension generated by cavitron ultrasonic surgical aspirator in pediatric brain tumors / $c M. Vaskova, M. Tichy, J. Zamecnik, P. Liby, D. Kuzilkova, A. Vicha, J. Hrabeta, T. Kalina, J. Stary, O. Hrusak,
520    9_
$a PURPOSE: The aim of this study was to test the possibility of using specimens obtained by a cavitron ultrasonic surgical aspirator (CUSA) in flow and mass cytometry investigations of pediatric brain tumors. METHODS: CUSA specimens obtained from 19 pediatric patients with brain tumors were investigated. Flow and mass cytometry methods were applied to analyze the composition of material collected using the CUSA. Cell suspensions were prepared from CUSA aspirates. Then sample viability was assessed by conventional flow cytometry and subsequently stained with a panel of 31 metal-labeled antibodies. RESULTS: Viability assessment was performed using conventional flow cytometry. Viability of cells in the acquired samples was below 50% in 16 of 19 cases. A mass cytometry investigation and subsequent analysis enabled us to discriminate brain tumor cells from contaminating leukocytes, whose proportions varied across the specimens. The addition of the viability marker cisplatin directly into the mass cytometry panel gave the means to selecting viable cells only for subsequent analyses. The proportion of non-viable cells was higher among tumor cells compared leukocytes. CONCLUSIONS: When the analysis of the tumor cell immunophenotype is performed with markers for determining viability, the expression of the investigated markers can be evaluated. Suitable markers can be selected by high-throughput methods, such as mass cytometry, and those that are diagnostically relevant can be investigated using flow cytometry, which is more flexible in terms of time.
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a nádory mozku $x diagnóza $x metabolismus $x patologie $x chirurgie $7 D001932
650    _2
$a viabilita buněk $7 D002470
650    _2
$a cisplatina $x metabolismus $7 D002945
650    _2
$a průtoková cytometrie $7 D005434
650    _2
$a lidé $7 D006801
650    _2
$a leukocyty $x metabolismus $x patologie $7 D007962
650    _2
$a neurochirurgické výkony $x přístrojové vybavení $7 D019635
650    _2
$a analýza jednotlivých buněk $7 D059010
650    _2
$a ultrazvuková terapie $x přístrojové vybavení $7 D014464
655    _2
$a časopisecké články $7 D016428
700    1_
$a Tichy, Michal $u Department of Neurosurgery, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Zamecnik, Josef $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Liby, Petr $u Department of Neurosurgery, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Kuzilkova, Daniela $u CLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Vicha, Ales $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Hrabeta, Jan $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Kalina, Tomas $u CLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Stary, Jan $u Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Hrusak, Ondrej $u CLIP - Childhood Leukaemia Investigation Prague, Prague, Czech Republic. Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic.
773    0_
$w MED00002827 $t Journal of neuro-oncology $x 1573-7373 $g Roč. 143, č. 1 (2019), s. 15-25
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30827009 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20201015161708 $b ABA008
999    __
$a ok $b bmc $g 1451399 $s 1073289
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 143 $c 1 $d 15-25 $e 20190302 $i 1573-7373 $m Journal of neuro-oncology $n J Neurooncol $x MED00002827
GRA    __
$a 15-26588A $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a UNCE 204012 $p Univerzita Karlova v Praze
GRA    __
$a LO1604 $p Ministerstvo Školství, Mládeže a Tělovýchovy
GRA    __
$a NV15-26588A $p MZ0
LZP    __
$a Pubmed-20191007

Find record

Citation metrics

Logged in users only

Archiving options